STERIMED
Acquired by
SAGARD
STERIMED acquired by SAGARD
Target
STERIMED
Acquirer
SAGARD
Context
Sterimed, a global leader in medical sterilization packaging, has entered into exclusive negotiations with Sagard to organize a secondary LBO. This transaction facilitates the exit of Meeschaert Capital Partners, which held a majority stake since 2016 following the group's spin-off from ArjoWiggins. The current management team, led by CEO Thibaut Hyvernat, will remain significantly invested in this new chapter.
This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 13.4x since the beginning of 2026, 1.2% decrease compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
A global leader in the manufacturing of medical sterilization packaging solutions. Sterimed designs, produces, and markets high-performance packaging materials (paper, film, and complex materials) used by medical device manufacturers and hospitals to maintain the sterility of instruments. The group operates several production sites worldwide (France, China, USA, Mexico).
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with STERIMED
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 04/2025 | IK PARTNERS | STERIMED | FRANCE | Medical Consumables | Sterimed completes its third buy-out (LBO) as IK Partners returns as the majority shareholder, taking over from Sagard. This transaction values the group at over EUR1 billion, a significant jump from its previous valuation. Under Sagard's ownership, Sterimed accelerated its international expansion, notably in North America and Asia. The new partnership with IK Partners aims to further consolidate the medical packaging market through a global buy-and-build strategy and to invest in sustainable, eco-friendly sterilization solutions. |
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.